Aaron D. Pearson, Ph.D.
Affiliations: | 2013 | Chemistry | Colorado State University, Fort Collins, CO |
Google:
"Aaron Pearson"Mean distance: 8.84 | S | N | B | C | P |
Parents
Sign in to add mentor| Robert Michael Williams | grad student | 2013 | Colorado State | |
| (Approaches towards the synthesis of saxitoxin alkaloids.) | ||||
| Peter G. Schultz | post-doc | 2013-2015 | Scripps Institute | |
| (Trapping a transition state in a computationally designed protein bottle) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Martínez-Peña F, Pearson AD, Tang EL, et al. (2022) Synthesis and biological evaluation of novel FiVe1 derivatives as potent and selective agents for the treatment of mesenchymal cancers. European Journal of Medicinal Chemistry. 242: 114638 |
| Bollong MJ, Pietilä M, Pearson AD, et al. (2017) A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proceedings of the National Academy of Sciences of the United States of America |
| Yu S, Pearson A, Lim R, et al. (2017) P-262 A PDE4 Inhibitor-antibody Conjugate for Treating Ulcerative Colitis Inflammatory Bowel Diseases. 23 |
| Yu S, Pearson AD, Lim RK, et al. (2016) Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Pearson AD, Mills JH, Song Y, et al. (2015) Transition states. Trapping a transition state in a computationally designed protein bottle. Science (New York, N.Y.). 347: 863-7 |
| Pearson AD, Williams RM. (2014) Synthetic studies towards Zetekitoxin AB: preparation of 4,5-epi-11-hydroxy-saxitoxinol. Tetrahedron. 70: 7942-7949 |
| Barone G, Anderson J, Pearson AD, et al. (2013) New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5814-21 |
| Berry T, Luther W, Bhatnagar N, et al. (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 22: 117-30 |